Olympus has partnered with Revival Healthcare Capital to launch a joint venture focused on introducing robotic technology to gastrointestinal (GI) procedures.
The new company, Swan EndoSurgical, aims to develop a minimally invasive endoluminal platform designed to navigate the GI tract like a conventional endoscope—but with the added capability of deploying flexible robotic arms. These robotic tools will enable physicians to treat tumors, lesions, and other GI conditions more effectively. The startup will be headquartered in Boston, with a dedicated technology center in Cambridge, U.K.
Olympus will hold a “significant equity stake” and contribute its expertise in visualization and GI endoscopy technologies. Revival Healthcare, meanwhile, will retain majority ownership. The two partners have committed an initial investment of $65 million, with the potential to increase funding to $458 million upon reaching key development milestones.
“We’re excited about this collaboration, which we believe will reshape the GI landscape by expanding physicians’ procedural capabilities,” said Olympus CEO Bob White. “This platform enables transformative, organ-sparing care with the potential to improve outcomes for a wide range of patients.”
As part of the agreement, Olympus retains the option to acquire Swan at a predetermined valuation if the venture proves successful. Should Olympus decline, Revival will maintain full ownership rights.
“This strategic collaboration positions Swan—and Olympus, as a potential future owner—for long-term success,” said Rick Anderson, Chairman of Revival. “Our shared commitment to advancing endoluminal robotics will ultimately benefit patients and healthcare providers worldwide.”